Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/653
Login to MRSPTU Repository
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Machhi, J | - |
dc.contributor.author | Shahjin, F | - |
dc.contributor.author | Das, S | - |
dc.contributor.author | Patel, M | - |
dc.contributor.author | Cohen, J D | - |
dc.contributor.author | Singh, P A | - |
dc.contributor.author | Baldi, A | - |
dc.contributor.author | Bajwa, N | - |
dc.contributor.author | Kumar, R | - |
dc.contributor.author | Vora, L K | - |
dc.date.accessioned | 2023-07-18T06:54:35Z | - |
dc.date.available | 2023-07-18T06:54:35Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1872-8294 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0169409X21000028?via%3Dihub | - |
dc.description.abstract | The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Advanced Drug Delivery Reviews,171 | en_US |
dc.subject | Nanocarrier vaccines | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.title | Nanocarrier vaccines for SARS-CoV-2 | en_US |
dc.type | Article | en_US |
Appears in Collections: | Research Papers |
Login to MRSPTU Repository
There are no files associated with this item.
Items in MRSPTU Repository are protected by copyright, with all rights reserved, unless otherwise indicated.